Last reviewed · How we verify
Grazax
At a glance
| Generic name | Grazax |
|---|---|
| Also known as | Grazax 75,000 SQ-T oral lyophilisate, Allergen Immunotherapy Tablet, SQ Standardized Grass Allergy Immunotherapy, Grazax Placebo tablet, grass pollen allergen sublingual immunotherapy (SLIT) |
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Identification of B Regulatory Cells by Flow Cytometry
- Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (PHASE2)
- Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT (PHASE2, PHASE3)
- Tolerability of Grazax in Patients With Hayfever in Real Life Settings (PHASE4)
- Standardising Nasal Allergen Challenge in Adult With Hay Fever (NA)
- Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study (PHASE2)
- Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® (PHASE4)
- Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Grazax CI brief — competitive landscape report
- Grazax updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI